Skip to main content
. 2021 Feb 4;556:133–139. doi: 10.1016/j.virol.2021.01.015

Fig. 4.

Fig. 4

Molecular docking showing the interactions between SARS-CoV-2 S2 subunit [6LXT] and robustaflavone (4): 3-dimensional structures of (a) SARS-CoV-2 S2 subunit [6LXT] and (b) robustaflavone (4) before docking study. (c) 3-dimensional representation of [6LXT]-docked structure of (4). (d) Surface representation of the 6LXT-robustaflavone binding, showing the active sites. (e) Ribbon docking model showing interactions between the active site residues of 6LXT and (4) (f) Close-up view.